Cannabinoids in the treatment of pain and spasticity in multiple sclerosis

Current Opinion in Investigational Drugs

Volumn 3, Issue 6, 2002, Pages 859-864

  Smith, Paul F ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

9 THC; Cannabinoid; EAE; Multiple sclerosis; Pain; Spasticity

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANTICONVULSIVE AGENT; BACLOFEN; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS; CARBAMAZEPINE; CODEINE; DANTROLENE; DELTA 8 TETRAHYDROCANNABINOL 11 OIC ACID; DEXANABINOL; DIAZEPAM; DRONABINOL; FLUOXETINE; LEVONANTRADOL; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PAROXETINE; PETHIDINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VALPROIC ACID;

AEROSOL; AGONIST; ANALGESIC ACTIVITY; BALANCE DISORDER; BODY POSTURE; CANCER PAIN; CANCER RISK; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFECT; DRUG FORMULATION; DRUG PREFERENCE; DRUG RECEPTOR BINDING; DRUG TARGETING; DYSPHORIA; HUMAN; LUNG CANCER; MENTAL DISEASE; MOTOR CONTROL; MULTIPLE SCLEROSIS; NOCICEPTION; NONHUMAN; PAIN; RELIABILITY; RESPIRATORY FUNCTION DISORDER; REVIEW; SEDATION; SIDE EFFECT; SMOKING; SPASTICITY; STAGING;

ANALGESICS, NON-NARCOTIC; ANIMALS; CANNABINOIDS; CANNABIS; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; FATTY ACIDS, UNSATURATED; HUMANS; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; PAIN; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SPASM; TETRAHYDROCANNABINOL;

EID: 0036628334     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. British Medical Association: Therapeutic Uses of Cannabis. Harwood Academic Publishers, the Netherlands (1997). Excellent review of the potential therapeutic effects of cannabinoids.
2. Hall WD, Degenhardt LJ, Currow D: Allowing the medical use of cannabis. Med J Aust (2001) 175:39-40.
3. Masood E: Cannabis laws 'threaten validity of trials'. Nature (1998) 396:206.
4. Dyer O: Cannabis trial launched in patients with MS. Br Med J (2001) 322:192.
5. Gaoni Y, Mechoulam R: Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc (1964) 86:1646.
6. Mechoulam R: Marijuana chemistry. Science (1970) 168:1159-1166.
7. Mechoulam R, Braun P, Gaoni Y: Syntheses of Δ-1-tetrahydrocannabinol and related cannabinoids. J Am Chem Soc (1974) 94:6159-6165.
8. Mechoulam R, Devane WA, Breuer A, Zahalka J: A random walk through a cannabis field. Pharmacol Biochem Behav (1991) 40: 461-464.
9. Thomas BF, Compton DR, Martin BR: Characterization of the lipophilicity of natural and synthetic analogs of delta-9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther (1990) 255:624-630.
10. Howlett AC: Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci (1984) 35:1803-1810.
11. Howlett AC, Fleming RM: Cannabinoid inhibition of adenylate cyclase - Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol (1984) 26:532-538.
12. Elphick MR, Egertova M: The neurobiology and evolution of cannabinoid signalling. Philos Trans Royal Soc Lond - Series B: Biol Sci (2001) 356:381-408. Comprehensive and stimulating review of the cannabinoid receptor and endocannabinoid literature, which also speculates on the postsynaptic release of endocannabinoids.
13. 3H]-5′-trimethylammonium Δ8-tetrahydrocannabinol. J Pharmacol Exp Ther (1985) 234:784-791.
14. Devane WA, Dysarz 3rd FA, Johnson MR, Melvin LS, Howlett AC: Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol (1988) 34:605-613. First study to demonstrate cannabinoid receptors in the brain.
15. Bidaut-Russell M, Devane WA, Howlett AC: Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. J Neurochem (1990) 55:21-26.
16. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, De Costa BR, Rice KC: Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA (1990) 87:1932-1936. Seminal autoradiographic study of the distribution of cannabinoid receptors in the brain.
17. Herkenham M, Lynn AB, Johnson MR, Melvin LS, De Costa BR, Rice KC: Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci (1991) 11:563-583.
18. Mailleux P, Vanderhaeghen JJ: Distribution of neuronal cannabinoid receptor in the audit brain: A comparative receptor binding autoradiography and in situ hydridization histochemistry. Neuroscience (1992) 48:655-668.
19. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 346:561-564. First study reporting the cloning of the cannabinoid receptor gene.
20. Gerard CM, Mollereau C, Vassart G, Parmentier M: Nucleotide sequence of a human cannabinoid receptor. Nucl Acids Res (1990) 18:7142.
21. Onaivi ES, Chakrabarti A, Chaudhuri G: Cannabinoid receptor genes. Prog Neurobiol (1996) 48:275-305.
22. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365:61-65. First paper to report the peripheral cannabinoid receptor.
23. Lynn AB, Herkenham M: Localization of cannabinoid receptors and non-saturable high density cannabinoid binding sites in peripheral tissues of the rat: Implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther (1994) 268:1612-1623.
24. 2 cannabinoid receptor mRNA in adult retina. Vis Neurosci (2000) 17:91-95.
25. 1 cannabinoid receptor in macrophage-like cells from brain tissue - Immunochemical characterization by fusion protein antibodies. J Neuroimmunol (1998) 82:13-21.
26. 1 cannabinoid receptors in cultured astrocytes. Eur J Neurosci (1999) 11:691-699.
27. 2 receptors. Proc Natl Acad Sci USA (1999) 96:14136-14141.
28. Piomelli D, Giuffrida A, Calignano A, Rodriguez De Fonseca F: The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci (2000) 21:218-224. Recent review of the potential therapeutic importance of the endocannabinoid system.
29. Breivogel CS, Griffin G, Di Marzo V, Martin BR: Evidence for a new G-protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol (2001) 60:155-163.
30. Mackie K, Hille B: Cannabinoids inhibit N-type calcium channels in neuroblastoma cells. Proc Natl Acad Sci USA (1992) 89:3825-3829. Example of the evidence that cannabinoids can inhibit voltage-dependent calcium channels.
31. Caufield MP, Brown DA: Cannabinoid receptor agonists inhibit calcium current in NG108-15 neuroblastoma cells via a pertusis toxin-sensitive mechanism. Br J Pharmacol (1992) 106:231-232.
32. Deadwyler SA, Hampson RE, Bennett BA, Edwards TA, Mu J, Pacheco MA, Ward SJ, Childers SR: Cannabinoids modulate potassium current in cultured hippocampal neurons. Receptors and Channels (1993) 1:121-134. Example of the evidence that cannabinoids modulate potassium channels.
33. Corchero J, Fuentes JA, Manzanares J: Δ-9-tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus. Eur J Pharmacol (1997) 323:193-195.
34. 1 cannabinoid receptor is coupled to the activation of c-Jun terminal kinase. Mol Pharmacol (2000) 58:814-820.
35. Arnold JC, Topple AN, Mallet PE, Hunt GE, McGregor IS: The distribution of cannabinoid-induced Fos expression in rat brain: Differences between the Lewis and Wistar strain. Brain Res (2001) 921:240-255.
36. Ameri A: The effects of cannabinoids on the brain. Prog Neurobiol (1999) 58:315-348. Recent comprehensive review of the neural effects of cannabinoids.
37. Guzman M, Galve-Roperh I, Sanchez C: Ceramide: A new second messenger of cannabinoid action. Trends Pharmacol Sci (2001) 22:19-22.
38. 1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration. J Neurosci (2001) 21:8758-8764.
39. 1 cannabinoid receptor can sequester G proteins, making them unavailable to couple to other receptors. J Neurosci (1999) 19:9271-9280.
40. Levenes C, Daniel H, Soubrie P, Crepel F: Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J Physiol (Lond) (1998) 510:867-879.
41. Vaughan CW, Connor M, Bagley EE, Christie MJ: Actions of cannabinoids on membrane properties and synaptic transmission in rat periacqueductal gray neurons in vitro. Mol Pharmacol (2000) 57:288-295. Important paper on the effects of cannabinoids in the periacqueductal gray region.
42. 1 in the hippocampus.
43. Roth S: Stereoselective presynaptic inhibitory effect of Δ-9-tetrahydrocannabinol on cholinergic transmission in the myenteric plexus of the guinea pig. Can J Physiol Pharmacol (1978) 56:968-975.
44. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R: Isolation and structure of brain constituent that binds to the cannabinoid receptor. Science (1992) 258:1946-1949. First report of an endogenous cannabinoid.
45. Thomas BF, Adams IB, Mascarella W, Martin BR, Razdan RK: Structure-activity analysis of anandamide analogs: Relationship to a cannabinoid pharmacophore. J Med Chem (1996) 39:471-479.
46. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D: Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (1994) 372:686-691.
47. Kruszka KK, Gross RW: The ATP- and CoA-independent synthesis of arachidonylethanolamide. A novel mechanism underlying the synthesis of the endogenous ligand of the cannabinoid receptor. J Biol Chem (1994) 269:14325-14348.
48. Mechoulam R, Fride E, Di Marzo V: Endocannabinoids. Eur J Pharmacol (1998) 359:1-18. Excellent review of the endocannabinoid family.
49. Felder CC, Nielsen A, Briley EM, Palkovits M, Priller J, Axelrod J, Nguyen DN, Richardson JM, Riggin RM, Koppel GA, Paul SM, Becker GW: Isolation and measurement of the endogenous cannavinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett (1996) 393:231-235.
50. Khanolkar AD, Makrivannis A: Structure-activity relationships of anandamide, on endogeneous cannabinoid ligand. Life Sci (1999) 65:607-616.
51. Palmer SL, Khanolkar AD, Makriyannis A: Natural and synthetic cannabinoids and their structure-activity relationships. Curr Pharmac Des (2000) 6:1381-1397.
52. Maccarrone M, Van Der Stelt M, Rossi A, Veldink GA, Vliegenthart JF, Agro AF: Anandamide hydrolysis by human cells in culture and brain. J Biol Chem (1998) 273:32332-32339.
53. 1 receptor in rat brain. Proc Royal Soc Lond Series B: Biol Sci (1998) 265:2081-2085. Seminal paper on the enzyme which is thought to break down anandamide.
54. Adams IB, Martin BR: Cannabis: Pharmacology and toxicology in animals and humans. Addiction (1986) 91:1585-1614.
55. Rodriguez De Fonseca F, Del Arco I, Martin-Calderon JL, Gorrtit MA, Navarro M: Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis (1998) 5:483-501.
56. Newsham-West D, Darlington CL, Smith PF: Potent effects of a selective cannabinoid receptor agonist on some medial vestibular nucleus neurons. Eur J Pharmacol (1998) 348:R1-R2.
57. Walker JM, Hohmann AG, Martin WJ, Strangman NM, Huang SM, Tsou K: The neurobiology of cannabinoid analgesia. Life Sci (1999) 65:665-673.
58. Rice AS: Cannabinoids and pain. Curr Opin Invest Drugs (2001) 2:399-414.
59. Pertwee RG: Cannabinoid receptors and pain. Prog Neurobiol (2001) 63:569-611. Authoritative review of the analgesic effects of cannabinoids.
60. Howlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR, Herkenham M: The cannabinoid receptor: Biochemical, anatomical and behavioral characterization. Trends Neurosci (1990) 13:420-423.
61. Petro DJ, Ellenberger C: Treatment of human spasticity with Δ-9-tetrahydrocannabinol. J Clin Pharmacol (1981) 21:413S-416S.
62. Ungerleider JT, Andrysiak T, Fairbanks L, Ellison GW, Myers LW: Δ-9-tetrahydrocannabinol in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse (1988) 7:39-50.
63. Greenberg HS, Werness SAS, Pugh JE, Andrus RO, Anderson DJ, Domino EA: Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharm Ther (1994) 55:324-328. These three studies reporter in references [62], [63] and [64] represent the few studies of the effects of cannabinoids on spasticity in humans
64. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Hayward L: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature (2000) 404:84-87. Important animal study of the effects of cannabinoids on spasticity.
65. 1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal of multiple sclerosis. Synapse (2001) 41:195-202.
66. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V: Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J (2001) 15:300-302. Important animal study of the effects of cannabinoids on spasticity.
67. Welch SP, Dunlow LD, Patrick GS, Razdan RK: Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to Δ-t-tetrahydrocannabinol after intrathecal administration to mice: Blockade of Δ-9-tetrahydrocannbinol-induced antinociception. J Pharmacol Exp Ther (1995) 273:1235-1244.
68. Calignano A, La Rana G, Giuffrida A, Piomelli D: Control of pain initiation by endogenous cannabinoids. Nature (1998) 394:277-281. Important paper on the potential role of endocannabinoids in the generation of pain.
69. Campbell FA, Tramer MR, Caroll D, Reynolds DJ, Moore RA, McQuay HJ: Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Br Med J (2001) 323:13-16. This paper is an excellent meta-analysis of the clinical literature on the analgesic effects of cannabinoids in comparison with conventional analgesics.
70. Williamson EM, Evans FJ: Cannabinoids in clinical practice. Drugs (2000) 60:1303-1314.
71. Chaperon F, Thiebot MH: Behavioural effects of cannabinoid agents in animals. Crit Rev Neurobiol (1999) 13:243-281.
72. Vaughan CW, Christie MJ: An analgesic role for cannabinoids. Med J Aust (2000) 173:270-272.
73. Consroe P, Musty R, Rein J, Tillery W, Pertwee R: The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol (1997) 38:44-48. Interesting on the perceived effects of cannabis on the symptoms of MS.
74. Voth EA, Schwartz RH: Medicinal applications of Δ-9-tetrahydrocannabinol. Ann Int Med (1997) 126:791-798.
75. Haubrich DR, Ward SJ, Baizman E, Bell MR, Bradford J, Ferrari R, Miller M, Perrone M, Pierson AK, Saelens JK, Luttinger D: Pharmacology of pravadoline:A new analgesic agent. J Pharmacol Exp Ther (1990) 255:511-522.
76. Ward SJ, Mastriani D, Casiano F, Arnold R: Pravadoline: Profile in isolated tissue preparations. J Pharmacol Exp Ther (1990) 255:1230-1239.
77. D'Ambra TE, Estep KG, Bell MR, Eissenstat MA, Josef KA, Ward SJ, Haycock DA, Baizman ER, Casiano FM, Beglin NC , Chippari SM, Grego JD, Kullnig RK, Daley GT: Conformationally restrained analogues of pravadoline: Nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem (1992) 35:124-135.
78. Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR: Aminoalkylindole analogs: Cannabimimetic activity of a class of compounds structurally distinct from Δ-9-tetrahydrocannabinol. J Pharmacol Exp Ther (1992) 263:1118-1126.